peterschreiber.media William Blair initiated coverage of Tenaya Therapeutics ( NASDAQ: TNYA ) with an outperform rating, citing its gene therapy candidate TN-201. The investment firm believes TN-201 could reverse cardiac hypertrophy and provide durable improvements in cardiac function in patients with MYBPC3-associated hypertrophic cardiomyopathy.
William Blair also said it sees upcoming Phase 1 data for the product, expected in the second half of 2024, to provide “insight into TN-201’s therapeutic benefit and be a major catalyst for the stock.” More on Tenaya Therapeutics Seeking Alpha’s Quant Rating on Tenaya Therapeutics Historical earnings data for Tenaya Therapeutics Financial information for Tenaya Therapeutics.
